Author: David Vogel

MedAvante Surpasses 630,000 Electronic Source (eSource) Clinical Trial Assessments

Extends Leadership Position in Electronic Clinical Outcome Assessments (eCOA)

Hamilton, NJ (November 15, 2016) — MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, announced significant advances in the deployment of the groundbreaking Virgil® Investigative Study Platform for global clinical trials as the source (eSource) data platform begins its third year in worldwide use.

MedAvante Unveils Updated Virgil eSource Platform to Further Streamline User Experience, Enhance Data Quality

Hamilton, NJ (October 6, 2016) — MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, announced today the newest release of the Virgil Investigative Study Platform.

MedAvante Presents Research on Preventing PANSS Errors at ISCTM Fall Conference

MedAvante Presents Research on Preventing PANSS Errors at ISCTM Fall Conference.

Continue reading

The Rest is Noise: The Promise of eCOA in Increasing Signal Detection

By Christopher Randolph, PhD, ABPP-CN, Medical Director of Neuropsychology, Loyola University Medical Center, VP of Neurocognition, MedAvante.

Go to download page

“Innovation is Everyone’s Job:” MedAvante CEO Paul Gilbert Offers Take on Jumpstarting Innovation at Avoca Quality Consortium

MedAvante, Inc. CEO Paul Gilbert encouraged Pharma industry leaders to challenge conventional thinking during his panel appearance at the Fifth Annual Avoca Quality Consortium Summit in Princeton, NJ.

The panel, “Innovative Collaborations in the Design and Integration of Quality in Clinical Operations,” explored the intersection of innovation, quality, and compliance.

In a dialogue with panel moderator Rob Metcalf, PhD (Vice President of Global Regulatory Affairs, Eli Lilly), Neil McCullough, PhD, MSc (Executive Vice President for Quality Assurance, ICON) and Grace Crawford, (Vice President for Clinical Quality & Compliance, MedImmune), Gilbert urged the industry to rethink an ingrained aversion to risk.

Citing common challenges like committee thinking and changing management trends, Gilbert reminded the audience that failure creates “the prospect of triumph, innovation, and change.” Gilbert stated that the responsibility for improving the industry has to be shared, and cannot be delegated to one individual or department. Innovation, he emphasized, is “everyone’s job.”

Gilbert and his co-founder Amy Ellis have been driving innovations in the Pharma industry for over a decade. First, MedAvante introduced Central Ratings to limit bias and subjectivity in trial assessment. More recently, the company has been the leading innovator in eSource – digital data capture – which has significantly advanced quality in clinical trials.

MedAvante was the first to develop an eSource solution for clinician-reported outcomes in 2009, partnering their 200+ in-house clinicians with software designers to create the Virgil Investigative Study Platform. This innovation enabled MedAvante clinicians’ firsthand knowledge of site workflow and operations to be built into the Virgil Platform.

MedAvante is a proud associate member of the Avoca Quality Consortium. Led by the Avoca Group, the Consortium convenes leaders from over 55 pharma, biotech, and clinical service companies to share knowledge and drive quality and innovation in clinical trials.

Virgil Improves Signal Detection by Minimizing Scoring Discrepancies in AD Clinical Trials

MedAvante research at Alzheimer’s Association International Conference (AAIC) shows Virgil improves signal detection by minimizing scoring discrepancies in AD clinical trials.